14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
GLPG vs PVLA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Galapagos NV (GLPG) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). GLPG carries a Unified Composite Score of 61.5/100 (BUY) at $27.73 (N/M Forward P/E, 88.0% operating margin), whereas PVLA carries 48.9/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin).
Technical & Structure Timing Caution: GLPG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.5); meanwhile PVLA is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GLPG vs PVLA. Trailing 12-month operating profitability (GLPG 88.0% vs PVLA 0.0%) and valuation multiples (GLPG N/M vs PVLA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $2.2B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ GLPG vs PVLA Key Questions & Quantitative Answers
As of Nov 16, 2026, Galapagos NV (GLPG) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). GLPG carries a Unified Composite Score of 61.5/100 (BUY) at $27.73 (N/M Forward P/E, 88.0% operating margin), whereas PVLA carries 48.9/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: GLPG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.5); meanwhile PVLA is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
GLPG leads the Growth & Scale pillar: GLPG posts +1093.2% YoY revenue growth and N/A YoY earnings growth on $602M TTM revenue (56.0% gross margin, 88.0% operating margin), compared with PVLA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, GLPG generates $602M in USD-normalized revenue versus N/A for PVLA. In operating R&D and SG&A reinvestment, GLPG deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PVLA.
GLPG screens cheaper on headline valuation multiples. GLPG trades at N/M Forward P/E, 5.1x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (51.1% EBITDA margin), whereas PVLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GLPG (10.4% ROE) versus PVLA (-63.4% ROE) capital efficiency.
In options market volatility and institutional positioning, GLPG carries 35.2% implied volatility (2nd %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 20% Vol realized risk). By comparison, PVLA carries 47.9% implied volatility (2nd %ile, Compressed (<25th %ile)), a 3.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.66β · 75% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.